PRE-INFORMED: A Preliminary Study for INFORMED
Study Details
Study Description
Brief Summary
Investigators will determine whether N-of-1 trials, as a pragmatic, patient-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased subject confidence regarding the decision to continue or discontinue beta-blockers in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
This is an unblinded NIH Stage I of Behavioral Intervention Development trial, using serial multiple-period single patient crossover design. Investigators will enroll 20 participants, conducting an N-of-1 trial in each of them. The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs. Off [B]) with up to 6 periods, each period lasting up to 6 weeks. The sequence of treatment will be randomized to either ABAB or BABA. Each participant will have the option to participate in additional periods if they wish to gather more data. The intervention drug will be beta-blockers, previously prescribed to the subjects by their physician. The investigators have developed a titration algorithm, where the participant's dose of beta-blocker will be decreased by 50% every week prior to their Off [B] period. Similarly, investigators will increase participant's beta-blocker dose by 50% every week prior to their On [A] period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Beta Blocker ABAB Sequence This arm will follow an ABAB sequence. "A" representing ON beta blockers and "B" representing OFF beta blockers. Participants in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. During Period 3, participants will restart beta-blockers, gradually up-titrating until reaching their home dose and finally during period 4, the investigators will again conduct a dose reduction until they are off of beta-blockers. If the subject chooses to continue into Period 5 the investigators will repeat the same up-titration process until the participant reaches their home dose, and finally during Period 6, the dose will be reduced until the participant is off of their beta-blocker. |
Drug: Beta blocker
The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.
Subjects will be randomized into either ABAB or BABA sequences.
Other names:
atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate
Other Names:
|
| Active Comparator: Beta Blocker BABA Sequence This arm will follow a BABA sequence. "A" representing ON beta blockers and "B" representing OFF beta blockers. Participants in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where up-titration will begin until they are back on their previously prescribed dose of beta blockers. During Period 3, the investigators will again conduct a dose reduction, until the participant is off of beta blockers and finally during Period 4, the investigators will up-titrate them back to their home dose of beta blockers. If the participant chooses to continue into Period 5 the investigators will repeat the same down-titration process until the participant is off their beta-blocker, and finally during Period 6, the dose will be increased until the participant is back to their home dose. |
Drug: Beta blocker
The intervention is a two-arm crossover withdrawal/reversal design (On [A] vs Off [B]) with up to 6 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta-blocker. During the Off period (B), their beta blockers will be down titrated and subsequently discontinued.
Subjects will be randomized into either ABAB or BABA sequences.
Other names:
atenolol betaxolol bisoprolol metoprolol nebivolol nadolol propranolol acebutolol penbutolol pindolol carvedilol labetalol sotalol metoprolol succinate metoprolol tartrate
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in patient's confidence regarding the decision to continue or discontinue beta-blocker, as assessed by qualitative interviews [Baseline, End of each period (approx. weeks 6, 12, 18, and 24), month 6 follow-up, month 9 follow-up, and month 12 follow-up]
- Change in patient decision-confidence, as measured by the Decisional Conflict Scale (DCS) [Baseline and End of Intervention (approx. week 12, 18, or 24)]
Measures participant perceptions of uncertainty in decision making, factors contributing to uncertainty, and effective decision making. A set of 16 questions with responses ranging from "strongly agree" = (0) to "strongly disagree" = (4). Scores are summed together to produce an overall score between 0 and 100. Lower scores indicate feeling informed and low decisional conflict whereas higher scores indicate feelings of uncertainty and high decisional conflict.
Secondary Outcome Measures
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [Baseline]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [End of Period 1 (approx. week 6)]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [End of Period 2 (approx. week 12)]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [End of Period 3 (approx. week 18)]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [End of Intervention (approx. week 24)]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [Month 6 follow-up]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [Month 9 follow-up]
- Features of a feasible and pragmatic protocol for deprescribing N-of-1 trials in patients with Heart Failure with Preserved Ejection Fraction, as measured by qualitative interviews [Month 12 follow-up]
- Change in patient's feeling informed through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale [Baseline and End of Intervention (approx. week 24)]
A set of 3 items within the Decisional Conflict Scale assessing participant's sense of knowing the options available to them and their benefits. Answers range from "strongly agree" = (0) to "strongly disagree" = (4). Scores are summed together to produce an overall score between 0 (feels extremely informed) and 100 (feels extremely uninformed).
- Change in patient's feeling uncertainty through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale [Baseline and End of Intervention (approx. week 24)]
A set of 3 items within the Decisional Conflict Scale assessing how sure participants feel about making a given decision. Answers range from "strongly agree" = (0) to "strongly disagree" = (4). Scores are summed together to produce an overall score between 0 (feels extremely certain about best choice) and 100 (feels extremely uncertain about best choice).
- Change in patient's feeling supported through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale [Baseline and End of Intervention (approx. week 24)]
A set of 3 items within the Decisional Conflict Scale assessing if participant's feel supported or pressured by others when making a given decision. Answers range from "strongly agree" = (0) to "strongly disagree" = (4). Scores are summed together to produce an overall score between 0 (feels extremely supported in decision making) and 100 (feels extremely unsupported in decision making).
- Change in patient's decision effectiveness through an N-of-1 protocol, as measured by the Decisional Conflict sub-scale [Baseline and End of Intervention (approx. week 24)]
A set of 4 items within the Decisional Conflict Scale assessing if participants feel satisfied and informed in their decision making. Answers range from "strongly agree" = (0) to "strongly disagree" = (4). Scores are summed together to produce an overall score between 0 (good decision) and 100 (bad decision).
- Change in shared decision making through an N-of-1 protocol, as measured by the 9-item Shared Decision-Making Questionnaire [Baseline and End of Intervention (approx. week 24)]
Measures patients' feeling of inclusion during the decision-making process of their treatment options. The 9-item questionnaire asks participants to respond to statements with answers to the questions ranging from "completely disagree" to "completely agree". Responses range from (0) = "completely disagree" to (5) = "completely agree" and are scored on a six-point Likert scale. Scores are summed together to produce an overall score between 0 (low involvement and 45 (high involvement).
- Change in patient activation through an N-of-1 protocol, as assessed by the Patient Activation Measure (PAM) [Baseline and End of Intervention (approx. week 24)]
Assesses an individual's knowledge, skills and confidence integral to managing one's own health and healthcare. Participants respond to a set of statements with answers ranging from "disagree strongly," "disagree," "agree," "strongly agree," and "not applicable." The responses are quantified to produce a score ranging from 0 to 100, and respondents fall into one of four levels of patient activation: Disengaged & Overwhelmed, Becoming Aware but still Struggling, Taking Action & Gaining Control, and Maintaining Behaviors & Pushing Further. A score of 0 (Disengaged & Overwhelmed) indicates low patient activation, patient is passive with low healthcare knowledge and adherence. A score of 100 (Maintaining Behaviors & Pushing Further) indicates high patient activation, with active maintenance of a healthy lifestyle.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Ambulatory adults age ≥ 65 years with HFpEF, according to ACC/AHA guidelines (signs and symptoms of heart failure AND ejection fraction ≥ 50%)
-
Taking beta-blocker
Exclusion Criteria:
-
Alternate causes of HFpEF Syndrome:
-
Severe aortic stenosis
-
Moderate-severe mitral stenosis
-
Constrictive pericarditis
-
High output HF
-
Infiltrative cardiomyopathy
-
Other compelling indication for beta-blocker
-
Prior EF < 50%
-
Hypertrophic cardiomyopathy
-
Angina symptoms
-
Acute coronary syndrome, myocardial infarction, or coronary artery bypass surgery in prior 3 years
-
History of ventricular tachycardia
-
Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year
-
Sinus tachycardia > 100 bpm, atrial arrhythmia with ventricular rate > 90 bpm, systolic blood pressure > 160 mmHg
-
Clinical instability (N-of-1 trials are appropriate for stable conditions only)
-
Decompensated heart failure
-
Hospitalization in past 30 days
-
Medication changes or procedures in prior 14 days that could confound observations/data, at PI discretion
-
Estimated life expectancy < 6 months
-
Moderate-severe dementia or psychiatric disorder precluding informed consent
-
Any condition that, in the Principal Investigator's opinion, makes the patient unsuitable for study participation
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Weill Cornell Medicine | New York | New York | United States | 10065 |
Sponsors and Collaborators
- Weill Medical College of Cornell University
- National Institute on Aging (NIA)
Investigators
- Principal Investigator: Parag Goyal, MD, MSc, Weill Medical College of Cornell University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 22-08025181
- 5K76AG064428-03